Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice
Clinical observations that kidney transplant recipients receiving belatacept who experienced T cell-mediated acute rejection can be successfully treated and subsequently maintained on belatacept-based immunosuppression suggest that belatacept is able to control memory T cells. We recently reported t...
Main Authors: | James S. Young, Stella H.-W. Khiew, Jinghui Yang, Augustin Vannier, Dengping Yin, Roger Sciammas, Maria-Luisa Alegre, Anita S. Chong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01169/full |
Similar Items
-
Targeting inflammation and immune activation to improve CTLA4-Ig-based modulation of transplant rejection
by: Marcos Iglesias, et al.
Published: (2022-09-01) -
Equal Expansion of Endogenous Transplant-Specific Regulatory T Cell and Recruitment Into the Allograft During Rejection and Tolerance
by: James S. Young, et al.
Published: (2018-06-01) -
Chronic CD40L blockade is required for long-term cardiac allograft survival with a clinically relevant CTLA4-Ig dosing regimen
by: Lukas W. Unger, et al.
Published: (2022-12-01) -
A Model for Apoptotic-Cell-Mediated Adaptive Immune Evasion via CD80–CTLA-4 Signaling
by: Abraam M. Yakoub, et al.
Published: (2019-05-01) -
Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis
by: Cayman Williams, et al.
Published: (2022-08-01)